These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 27507064)

  • 1. Bleeding complications with oral anticoagulants in the elderly: an observational study.
    Peeterbroeck J; Danguy C; Lelubre C; Meulemans M; Higuet S
    Geriatr Psychol Neuropsychiatr Vieil; 2016 Dec; 14(4):406-412. PubMed ID: 27507064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selection, management, and outcome of vitamin K antagonist-treated patients with atrial fibrillation not switched to novel oral anticoagulants. Results from the Dresden NOAC registry.
    Michalski F; Tittl L; Werth S; Hänsel U; Pannach S; Sahin K; Weiss N; Beyer-Westendorf J
    Thromb Haemost; 2015 Nov; 114(5):1076-84. PubMed ID: 25994496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Choice of New Oral Anticoagulant Agents Versus Vitamin K Antagonists in Atrial Fibrillation: FANTASIIA Study.
    Moreno-Arribas J; Bertomeu-González V; Anguita-Sanchez M; Cequier Á; Muñiz J; Castillo J; Sanchis J; Roldán I; Marín F; Bertomeu-Martínez V;
    J Cardiovasc Pharmacol Ther; 2016 Mar; 21(2):150-6. PubMed ID: 26229096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New oral anticoagulants for the prevention of thromboembolic complications in atrial fibrillation: a single centre experience.
    Gorczyca-Michta I; Wożakowska-Kapłon B
    Kardiol Pol; 2015; 73(2):85-93. PubMed ID: 25179482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence and consequences of resuming oral anticoagulant therapy following hematuria and risks of ischemic stroke and major bleeding in patients with atrial fibrillation.
    Wang CL; Wu VC; Huang YT; Chen YL; Chu PH; Kuo CF; Wen MS; Chang SH
    J Thromb Thrombolysis; 2021 Jan; 51(1):58-66. PubMed ID: 32409936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association Between Use of Non-Vitamin K Oral Anticoagulants With and Without Concurrent Medications and Risk of Major Bleeding in Nonvalvular Atrial Fibrillation.
    Chang SH; Chou IJ; Yeh YH; Chiou MJ; Wen MS; Kuo CT; See LC; Kuo CF
    JAMA; 2017 Oct; 318(13):1250-1259. PubMed ID: 28973247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical events preceding switching and discontinuation of oral anticoagulant treatment in patients with atrial fibrillation.
    Hellfritzsch M; Grove EL; Husted SE; Rasmussen L; Poulsen BK; Johnsen SP; Hallas J; Pottegård A
    Europace; 2017 Jul; 19(7):1091-1095. PubMed ID: 28641379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Characteristics And Health Care Resources In Patients Treated With Oral Anticoagulants: Evidences From Italian Administrative Databases.
    Degli Esposti L; Andretta M; Di Pasquale G; Gambera M; Saragoni S; Perrone V; Buda S
    Vasc Health Risk Manag; 2019; 15():429-437. PubMed ID: 31632047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
    Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
    Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment Changes among Users of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation.
    Hellfritzsch M; Husted SE; Grove EL; Rasmussen L; Poulsen BK; Johnsen SP; Hallas J; Pottegård A
    Basic Clin Pharmacol Toxicol; 2017 Feb; 120(2):187-194. PubMed ID: 27580086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use and Outcomes of Triple Antithrombotic Therapy with Non-Vitamin K Antagonists in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention.
    Casamira N; García-Camarero T; Montoro-Ronsano JB; Veiga G; Del Blanco BG; De La Torre JM; Gordon B; García-Dorado D; Sambola A
    Am J Med Sci; 2019 Aug; 358(2):95-103. PubMed ID: 31176420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SSRI co-medication with NOAC or VKA does not increase hospitalisation for bleeding: A retrospective nationwide cohort study in Austria 2010-2015.
    Sheikh Rezaei S; Mittlböck M; Reichardt B; Wolzt M
    Int J Geriatr Psychiatry; 2019 Aug; 34(8):1194-1199. PubMed ID: 30968457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of switching from vitamin K antagonists to dabigatran or rivaroxaban in daily care--results from the Dresden NOAC registry.
    Beyer-Westendorf J; Gelbricht V; Förster K; Ebertz F; Röllig D; Schreier T; Tittl L; Thieme C; Hänsel U; Köhler C; Werth S; Kuhlisch E; Stange T; Röder I; Weiss N
    Br J Clin Pharmacol; 2014 Oct; 78(4):908-17. PubMed ID: 24697922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug interactions with oral anticoagulants in German nursing home residents: comparison between vitamin K antagonists and non-vitamin K antagonist oral anticoagulants based on two nested case-control studies.
    Jobski K; Hoffmann F; Herget-Rosenthal S; Dörks M
    Clin Res Cardiol; 2020 Apr; 109(4):465-475. PubMed ID: 31286199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recanalization therapies in acute ischemic stroke patients: impact of prior treatment with novel oral anticoagulants on bleeding complications and outcome.
    Seiffge DJ; Hooff RJ; Nolte CH; Béjot Y; Turc G; Ikenberg B; Berge E; Persike M; Dequatre-Ponchelle N; Strbian D; Pfeilschifter W; Zini A; Tveiten A; Næss H; Michel P; Sztajzel R; Luft A; Gensicke H; Traenka C; Hert L; Scheitz JF; De Marchis GM; Bonati LH; Peters N; Charidimou A; Werring DJ; Palm F; Reinhard M; Niesen WD; Nagao T; Pezzini A; Caso V; Nederkoorn PJ; Kägi G; von Hessling A; Padjen V; Cordonnier C; Erdur H; Lyrer PA; Brouns R; Steiner T; Tatlisumak T; Engelter ST;
    Circulation; 2015 Sep; 132(13):1261-9. PubMed ID: 26232277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of oral anticoagulants in German nursing home residents: drug use patterns and predictors for treatment choice.
    Jobski K; Hoffmann F; Herget-Rosenthal S; Dörks M
    Br J Clin Pharmacol; 2018 Mar; 84(3):590-601. PubMed ID: 29148592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thromboembolic and bleeding complications during oral anticoagulation therapy in cancer patients with atrial fibrillation: a Danish nationwide population-based cohort study.
    Ording AG; Horváth-Puhó E; Adelborg K; Pedersen L; Prandoni P; Sørensen HT
    Cancer Med; 2017 Jun; 6(6):1165-1172. PubMed ID: 28544489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Oral anticoagulation in atrial fibrillation: differential therapy with non vitamin K antagonist oral anticoagulants (NOAC) and vitamin K antagonists (VKA)].
    Sucker C; Litmathe J; Berthold HK
    MMW Fortschr Med; 2019 Oct; 161(Suppl 6):15-23. PubMed ID: 31587168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New oral anti-coagulants versus vitamin K antagonists in high thromboembolic risk patients.
    Bellin A; Berto P; Themistoclakis S; Chandak A; Giusti P; Cavalli G; Bakshi S; Tessarin M; Deambrosis P; Chinellato A
    PLoS One; 2019; 14(10):e0222762. PubMed ID: 31589620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concerns about the use of new oral anticoagulants for stroke prevention in elderly patients with atrial fibrillation.
    Stöllberger C; Finsterer J
    Drugs Aging; 2013 Dec; 30(12):949-58. PubMed ID: 24170233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.